Cytek Biosciences 2025 Q2 Earnings Loss Narrows 50% as Revenue Slides 2.2%

Cytek Biosciences (CTKB) reported Q2 2025 earnings on August 7, 2025, with results reflecting a narrowed net loss but a revenue decline. The company cut losses by 50% to $0.04 per share and lowered full-year revenue guidance, reflecting ongoing challenges in a soft macro environment.

Revenue
Cytek’s total revenue for Q2 2025 came in at $45.60 million, a 2.2% decrease from $46.62 million in the same period a year ago. Product revenue amounted to $31.41 million, while service revenue totaled $14.19 million, together accounting for the full revenue stream. The decline was primarily driven by lower product sales in EMEA and APAC, partially offset by growth in the U.S. and in service revenue.

Earnings/Net Income
The company reported a net loss of $5.58 million, or $0.04 per share, for Q2 2025, compared to a $10.43 million, or $0.08 per share, loss in Q2 2024—a 46.5% reduction in net losses. While the improvement is notable, Cytek remains in a sustained net loss position, reporting losses in five consecutive years. Despite this, the firm managed to narrow its operating loss, which fell to $10.6 million from $8.5 million year-over-year.

Price Action
The stock of Cytek Biosciences gained 1.04% in the latest trading session and delivered a strong 9.58% return over the past week. Over the past month, the shares rose by 14.41%, showing resilience in the wake of the earnings report.

Post-Earnings Price Action Review
Despite a modest share price recovery, the post-earnings strategy of buying Cytek shares following a revenue increase quarter-over-quarter and holding for 30 days yielded no returns over the past three years. The strategy showed a CAGR of 0.00% and an excess return of -48.73%, underperforming the benchmark return of 48.73%. The approach was risk-averse, with zero volatility and no maximum drawdown, but it failed to capitalize on broader market gains.

CEO Commentary
Dr. Wenbin Jiang, CEO of Cytek Biosciences, highlighted the company’s progress despite a challenging macroeconomic environment. He pointed to steady growth in FSP unit placements and recurring revenue, as well as the successful launch of the Cytek Aurora Evo system. Looking ahead, the CEO emphasized innovation, global expansion, and recurring revenue growth as key priorities, expressing confidence in the long-term recovery of the instrument market.

Guidance
For full-year 2025, Cytek narrowed its revenue guidance to a range of $196 million to $205 million, representing -2% to +2% growth over 2024, assuming stable currency exchange rates. The company remains focused on long-term growth drivers such as market expansion, innovation, and recurring revenue growth.

Additional News
Cytek Biosciences announced a $4.5 million repurchase of its common stock in open market transactions during Q2 2025, signaling confidence in its shares. The company also expanded its installed base of instruments to 3,295 units, adding 146 new placements in the quarter. Additionally, Cytek launched the Aurora Evo system, an advanced flow cytometer offering faster throughput and enhanced resolution for small particle detection. These strategic moves aim to support long-term growth while improving operational efficiency and market positioning.